ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

UNCY vs ORGO // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Unicycive Therapeutics Inc. (NASDAQ) VS. Organogenesis Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: UNCY 2 — ORGO 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UNCY VS. ORGO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC UNCY ORGO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 17.10% -52.10 ORGO /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -23.21% — TIE /fcf-yield <GO>
Operating Margin — 7.90% — TIE /operating-margins <GO>
Net Profit Margin — 6.60% — TIE /net-margins <GO>
Revenue Growth (YoY) — 17.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.09 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 ORGO /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.5 15.6 +24.85 UNCY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $106.1M $105.4M $756.9K UNCY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR UNCY REV ORGO REV UNCY GROSS % ORGO GROSS % UNCY FCF ORGO FCF
FY 2025 $0 $564.2M — — -$31.3M -$24.5M
FY 2024 $0 $482.0M — 76.0% -$28.6M $4.2M
FY 2023 $675.0K $433.1M — — -$18.3M $30.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UNCY // BETA —
ORGO // BETA —